Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adamgammadex sodium dose-ranging reversal of deep rocuronium neuromuscular blockade at PTC 1-2
ChiCTR2000038391Phase 2Completed
- Sponsor
- Renji Hospital
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of adamgammadex in reversal of nondepolarizing neuromuscular blockade (6 arms), sponsored by Renji Hospital. Primary endpoint: Time from study drug administration to TOF ratio recovery to 0.9. Started Sep 2018; status: completed.
02
Drugs
adamgammadex
03
Conditions
reversal of nondepolarizing neuromuscular blockade
Beyond the preview
Go deeper on ChiCTR2000038391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038391.